Barclays downgrades Hikma to 'equalweight' on Generics concerns
5th Aug 2022 09:43
(Sharecast News) - Barclays downgraded Hikma Pharmaceuticals on Friday to 'equalweight' from 'overweight' and cut the price target to 1,750p from 2,250p as it said a lack of visibility in the generics division was a real concern.
Read moreHikma revenue flat, profits tumble in first half
4th Aug 2022 10:15
(Sharecast News) - Hikma shares were tumbling on Thursday morning after the pharmaceuticals company reported flat group revenue in its first half, at $1.21bn, as it slashed its guidance on its lagging generics business.
Read moreHikma's Siggi Olafsson stands down as CEO
24th May 2022 07:09
(Sharecast News) - Drugmaker Hikma Pharmaceuticals revealed on Tuesday that chief executive Siggi Olafsson has resigned from both the role and the company's board of directors in order to pursue other opportunities.
Read moreHikma cuts 2022 generics guidance due to drug launch delay
5th May 2022 08:02
(Sharecast News) - Hikma Pharmaceuticals cut guidance for its generics business on Thursday, citing a delay to a drug launch.
Read moreHikma shares fall as generics unit faces headwinds
29th Apr 2022 08:32
(Sharecast News) - Hikma Pharmaceuticals shares fell as the company reported headwinds at its generics business.
Read moreHikma gets preliminary approval from US FTC for Custopharm deal
20th Apr 2022 07:39
(Sharecast News) - Hikma Pharmaceuticals has received preliminary approval from the US Federal Trade Commission for the acquisition of sterile injectables company Custopharm Inc from Water Street Healthcare for up to $425m.
Read moreHikma Pharmaceutical delivers year of 'solid growth' and 'strategic momentum'
24th Feb 2022 07:58
(Sharecast News) - Drugmaker Hikma Pharmaceutical said on Thursday that it had delivered another successful year of "solid growth and continued strategic momentum", with both revenue and operating profits improving year-on-year.
Read moreHikma buys Teligent Canadian assets for $47.75m
17th Jan 2022 07:08
(Sharecast News) - Hikma Pharmaceuticals on Monday said it had agreed to buy the Canadian assets of Teligent for $45.75m after the US firm filed for Chapter 11 bankruptcy last year.
Read moreHikma launches new US injectables unit
10th Jan 2022 07:24
(Sharecast News) - Hikma Pharmaceuticals on Monday said it was expanding its injectables business with the launch of a new outsourced sterile compounding business in the US.
Read moreArecor flags milestone payment from Hikma in first half of next year
21st Dec 2021 15:55
(Sharecast News) - Biopharmaceutical company Arecor Therapeutics updated the market on its ongoing exclusive agreement with Hikma Pharmaceuticals to co-develop a new, ready-to-use injectable medicine on Tuesday.
Read moreHikma strikes exclusive license agreement with Richter for denosumab
9th Dec 2021 08:32
(Sharecast News) - Drugmaker Hikma Pharmaceuticals has entered into an exclusive license agreement with Gedeon Richter to commercialise the latter's denosumab products in the US.
Read moreHikma reports solid trading in year to date
4th Nov 2021 07:58
(Sharecast News) - Hikma Pharmaceuticals reiterated full-year guidance as the company reported solid trading across its business.
Read moreCiti sees room for upside surprise on sales at Hikma Pharmaceuticals
1st Nov 2021 13:52
(Sharecast News) - Analysts at Citi reiterated their 'buy' stance for shares of Hikma Pharmaceuticals ahead of the company's trading statement due out later in the same week.
Read moreHikma buys Custopharm for $375m
27th Sep 2021 07:05
(Sharecast News) - Hikma Pharmaceuticals said it was buying US firm Custopharm from Water Street Healthcare Partners for $375m on a debt and cash-free basis, with a further $50m payable on meeting certain commercial milestones.
Read moreHikma buys Custopharm for $375m
27th Sep 2021 07:05
(Sharecast News) - Hikma Pharmaceuticals said it was buying US firm Custopharm from Water Street Healthcare Partners for $375m on a debt and cash-free basis, with a further $50m payable on meeting certain commercial milestones.
Read more